Alpha Cognition, a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is scheduled to participate in the following investor conferences in January 2022:
LifeSci Advisors Partners Corporate Access Event, January 5-7
BIO Partnering at JPM, January 10-14
H.C. Wainwright 2022 BioConnect Conference, January 10-13
I’m expecting to hear big news on the development of $ACOG’s ALPHA-1062 and ALPHA-0602 products, which should provide a huge catalyst to see prices potentially retest highs near $1.84.
With a recent change of director at $ACOG, I’m also looking forward to hearing how the company plans to move forward in 2022. This should be an exciting year for the company.
$ACOG.V is currently trading at $1.06 and is valued at an MCAP of $65.19 million.
https://ceo.ca/@businesswire/alpha-cognition-announces-participation-in-january